Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$13.23 ▼ -0.09
(-0.68%)
MKT CAP: $1.85B • VOL: 4.70M
52W L $8 52W H $18
NTLA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $67.7M | $57.9M | $36.3M |
| YoY Revenue Growth % | +16.9% | +59.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$441.0M | -$534.3M | -$515.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$412.7M | -$519.0M | -$481.2M |
| EBITDA (Normalized) | -$440.1M | -$529.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$394.7M | -$348.9M | -$394.1M |
| Capital Expenditures (CapEx) | $1.1M | $5.8M | — |
| Free Cash Flow (FCF) | -$395.9M | -$354.7M | -$394.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $155.5M | $189.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $671.4M | $872.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NTLA.